GLP-1 craving effects may trace to a brain region called the lateral septum

In August 2026, an analysis published by The Conversation and republished by ScienceDaily pointed to a small brain region called the lateral septum as a likely control point for the reduced cravings some people describe while taking GLP-1 drugs such as Ozempic and Wegovy ^[1].

The piece, written by Robert Munn, a senior lecturer at the University of Otago, pulls together existing research rather than reporting a new human trial ^[1]. It argues that the lateral septum, a structure that links memory and motivation, sits between the brain's memory centers and the dopamine-producing areas that make rewards feel good ^[1].

GLP-1 agonists mimic the GLP-1 hormone, stimulate insulin release, slow digestion and increase feelings of fullness, and were first used to treat type 2 diabetes ^[1]. Weight loss emerged as an effect, in some cases close to what is seen after bariatric surgery ^[1]. Human studies show these drugs also reduce alcohol consumption, and animal studies suggest they reduce use of cocaine, amphetamines, opiates and nicotine ^[1].

The obvious places to look for that effect would be the ventral tegmental area and the nucleus accumbens, the dopamine regions long tied to reward ^[1]. But the analysis says those regions lack a significant density of GLP-1 receptors, making them an unlikely direct mechanism ^[1]. The lateral septum, one step upstream, is loaded with those receptors ^[1].

The lateral septum has a long history in research on emotion. In 1953, US researchers Joseph Brady and Walle Nauta coined the term "septal rage" after animals with damage there showed increased aggression, while direct stimulation of the region reduced aggression ^[1]. More recent work places it at the center of a network connecting many brain areas ^[1].

Much of its input comes from the hippocampus, known for episodic memory and for "place cells" that track location and time ^[1]. The case of Henry Molaison, known as patient HM, who could not form new memories after epilepsy surgery, helped establish that role ^[1]. The lateral septum has place cells too, but they respond strongly to rewards, adding "what is good in this place" to the hippocampus's "where and when am I" ^[1]. It then shares that information with dopamine-producing regions ^[1].

The evidence for the craving link is mostly from animals. Activating GLP-1 receptors directly in the lateral septum reduced food consumption in mice, and a study earlier this year reported the same for alcohol consumption in mice ^[1]. Munn writes that his own lab showed this year that GLP-1 drugs reduce a type of activity in the lateral septum that may keep it from communicating as effectively with other brain regions ^[1].

Why it matters for patients

For people taking semaglutide, sold as Ozempic and Wegovy, this analysis does not change what those drugs are approved for. It describes them as diabetes and weight-loss medications and reports no new approval for alcohol or substance use ^[1].

It does offer a possible explanation for something many patients describe: a dulling of interest in alcohol or other rewards. The strength of the evidence differs by substance. Alcohol has human studies behind it, while the findings for cocaine, amphetamines, opiates and nicotine come from preclinical animal studies ^[1].

The analysis gives no information on dose, timing or who might experience these effects, and it does not estimate how many people are affected. Whether the lateral septum works the same way in humans has not been reported.

What happens next

The analysis, published in August 2026, does not name any human trial now testing whether the lateral septum is the mechanism behind reduced cravings in people, and it gives no timeline for one ^[1]. It says the findings are reshaping how researchers think about reward and have put the spotlight firmly on the lateral septum, and that the work could open new approaches to treating addiction as well as obesity ^[1].